Digestive Endoscopy Unit, Pôle Digestif Paris-Bercy, Clinique Paris-Bercy, Charenton-le-Pont, France.
Digestive Endoscopy Unit, Pôle Digestif Paris-Bercy, Clinique Paris-Bercy, Charenton-le-Pont, France.
Lancet Gastroenterol Hepatol. 2023 Aug;8(8):726-734. doi: 10.1016/S2468-1253(23)00104-8. Epub 2023 Jun 1.
Artificial intelligence systems have been developed to improve polyp detection. We aimed to evaluate the effect of real-time computer-aided detection (CADe) on the adenoma detection rate (ADR) in routine colonoscopy.
This single-centre randomised controlled trial (COLO-GENIUS) was done at the Digestive Endoscopy Unit, Pôle Digestif Paris-Bercy, Clinique Paris-Bercy, Charenton-le-Pont, France. All consecutive individuals aged 18 years or older who were scheduled for a total colonoscopy and had an American Society of Anesthesiologists score of 1-3 were screened for inclusion. After the caecum was reached and the colonic preparation was appropriate, eligible participants were randomly assigned (1:1; computer-generated random numbers list) to either standard colonoscopy or CADe-assisted colonoscopy (GI Genius 2.0.2; Medtronic). Participants and cytopathologists were masked to study assignment, whereas endoscopists were not. The primary outcome was ADR, which was assessed in the modified intention-to-treat population (all randomly assigned participants except those with misplaced consent forms). Safety was analysed in all included patients. According to statistical calculations, 20 endoscopists from the Clinique Paris-Bercy had to include approximately 2100 participants with 1:1 randomisation. The trial is complete and registered with ClinicalTrials.gov, NCT04440865.
Between May 1, 2021, and May 1, 2022, 2592 participants were assessed for eligibility, of whom 2039 were randomly assigned to standard colonoscopy (n=1026) or CADe-assisted colonoscopy (n=1013). 14 participants in the standard group and ten participants in the CADe group were then excluded due to misplaced consent forms, leaving 2015 participants (979 [48·6%] men and 1036 [51·4%] women) in the modified intention-to-treat analysis. ADR was 33·7% (341 of 1012 colonoscopies) in the standard group and 37·5% (376 of 1003 colonoscopies) in the CADe group (estimated mean absolute difference 4·1 percentage points [95% CI 0·0-8·1]; p=0·051). One bleeding event without deglobulisation occurred in the CADe group after a large (>2 cm) polyp resection and resolved after a haemostasis clip was placed during a second colonoscopy.
Our findings support the benefits of CADe, even in a non-academic centre. Systematic use of CADe in routine colonoscopy should be considered.
None.
人工智能系统的开发旨在提高息肉检测的准确率。我们旨在评估实时计算机辅助检测(CADe)对常规结肠镜检查中腺瘤检测率(ADR)的影响。
这项单中心随机对照试验(COLO-GENIUS)在法国巴黎伯西消化内镜科、巴黎伯西诊所进行。所有年龄在 18 岁及以上、ASA 评分 1-3 分、计划行全结肠镜检查的连续个体均进行入组筛查。当盲肠到达且结肠准备合适时,符合条件的参与者被随机分配(1:1;计算机生成的随机数字列表)至标准结肠镜检查或 CADe 辅助结肠镜检查(GI Genius 2.0.2;美敦力)。参与者和细胞病理学家对研究分组设盲,而内镜医生不设盲。主要结局为改良意向治疗人群中的 ADR(所有随机分组参与者,除了那些同意书放错位置的患者)。所有纳入患者均进行安全性分析。根据统计计算,巴黎伯西诊所的 20 名内镜医生需要纳入大约 2100 名患者进行 1:1 随机分组。该试验已完成并在 ClinicalTrials.gov 注册,编号为 NCT04440865。
2021 年 5 月 1 日至 2022 年 5 月 1 日,对 2592 名参与者进行了入组评估,其中 2039 名被随机分配至标准结肠镜检查组(n=1026)或 CADe 辅助结肠镜检查组(n=1013)。标准组中有 14 名参与者和 CADe 组中有 10 名参与者因同意书放错位置而被排除,在改良意向治疗分析中,共有 2015 名参与者(979[48.6%]名男性和 1036[51.4%]名女性)。标准组的 ADR 为 33.7%(1012 次结肠镜检查中有 341 次),CADe 组为 37.5%(1003 次结肠镜检查中有 376 次)(估计平均绝对差值为 4.1 个百分点[95%CI 0.0-8.1];p=0.051)。在一次大息肉(>2cm)切除后,CADe 组中发生了 1 例无去球蛋白的出血事件,在第二次结肠镜检查中放置止血夹后出血得到解决。
我们的研究结果支持 CADe 的益处,即使在非学术中心也是如此。在常规结肠镜检查中应考虑系统性地使用 CADe。
无。